This product is freeze dried. All water molecules have been removed.
Every lot is tried & tested in a relevant biological assay.
- Frontali, N. et al. (1976) J. Cell Biol. 68, 462.
Do not shake or vortex.
Alomone Labs α-Latrotoxin activates P42/44 MAP kinase by inducing Ca2+ influx in RIN insulinoma cells.Cells were treated for 15 min with 35 mM K+ or 2 nM α-Latrotoxin (#LSP-130) in the presence or absence of 5 mM EGTA. Cell proteins were resolved by SDS-PAGE and probed with anti-phospho-P42/44 antibodies.Alomone Labs α-Latrotoxin elicits synaptic transmission.A. Superimposed current traces of post synaptic recording from dissociated hippocampal neurons in culture before (black) and after (red) application of α-Latrotoxin (#LSP-130). B. Individual post synaptic currents are magnified from A.
α-Latrotoxin is a 130 kDa protein toxin from the black widow spider venom and is the only protein in the venom that affects mammals.1,2 Application of the toxin to presynaptic preparations induces, after a delay, a huge increase in spontaneous neurotransmitter release, which can be evaluated by measuring the post synaptic response in the form of miniature end plate potentials. This toxin is widely used to induce and study neurotransmitter release, but the molecular mechanism of its action is not fully determined.
α-Latrotoxin is isolated according to a modified protocol as described by Frontali3 and Grasso4.
α-Latrotoxin (#LSP-130) is a highly pure, natural, and biologically active toxin.
- Lucas, S.J. et al. (2018) J. Physiol. 596, 1699.
- Negro, S. et al. (2017) EMBO Mol. Med. 9, 1000.
- Negro, S. et al. (2016) Front. Cell. Neurosci. 10, 134.
- Duregotti, E. et al. (2015) Proc. Natl. Acad. Sci. U.S.A. 112, E497.
- Duregotti, E. et al. (2013) Toxicon 64, 20.
- Jin, I. et al. (2012) Proc. Natl. Acad. Sci. U.S.A. 109, 9137.
- McGonigal, R. et al. (2010) Brain 133, 1944.
- Arunachalam L. et al. (2008) Mol. Biol. Cell 19, 722.
- Li G. et al. (2005) J. Neurosci. 25, 10188.
- Blair D. H. et al. (2003) Auton. Neurosci. 105, 45.
- Bullens R. W. M. et al. (2002) J. Neurosci. 22, 6876.
- Jacobs B.C. et al. (2002) Muscle Nerve 25, 549.
- Zygmunt P. M. et al. (2002) J. Neurosci. 22, 4720.
- O'Hanlon G. M. et al. (2001) Brain 124, 893.
- Brock J. A. et al. (2000) Br. J. Pharmacol. 131, 1507.
- Hogestatt E. D. et al. (2000) Br. J. Pharmacol. 130, 27.
- Diefenbach T. J. et al. (1999) J. Neurosci. 19, 9436.
- Plomp J.J. et al. (1999) Ann. Neurol. 45, 189.
- Zygmunt P. M. et al. (1999) Nature 400, 452.
- Boehm S. and Huck S. (1998) J. Neurochem. 71, 2421.
- Nakata T. et al. (1998) J. Cell Biol. 140, 659.
- De Potter W.P. et al. (1997) SYNAPSE 25, 44.
- Boehm S. and Huck S. (1996) Eur. J. Neurosci. 8, 1924.
- Waterman S. A., and C. A. Maggi (1995) Neuroscience 69, 977.
- Anti-Latrophilin-1 (LPHN1) (extracellular) Antibody (#ALR-021)
- Anti-Neurexin 1α (extracellular) Antibody (#ANR-031)
- Anti-Neurexin 1α (extracellular)-ATTO-488 Antibody (#ANR-031-AG)
- Anti-Neurexin 3α (extracellular) Antibody (#ANR-033)
- Anti-Synaptotagmin-1 (SYT1) Antibody (#ANR-003)
- Anti-Syntaxin 2 Antibody (#ANR-008)
- Anti-Syntaxin 3 Antibody (#ANR-005)